Cargando…

Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial

PURPOSE: Proton-pump inhibitors (PPIs) are frequently used to treat gastroesophageal reflux disease (GERD) in children, but recent evidence suggests a potential association between PPI treatment and some types of infections. The aim of this study was to assess the effectiveness of Lactobacillus rham...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziechciarz, Piotr, Krenke, Katarzyna, Szajewska, Hania, Horvath, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231745/
https://www.ncbi.nlm.nih.gov/pubmed/32483546
http://dx.doi.org/10.5223/pghn.2020.23.3.251
_version_ 1783535240824750080
author Dziechciarz, Piotr
Krenke, Katarzyna
Szajewska, Hania
Horvath, Andrea
author_facet Dziechciarz, Piotr
Krenke, Katarzyna
Szajewska, Hania
Horvath, Andrea
author_sort Dziechciarz, Piotr
collection PubMed
description PURPOSE: Proton-pump inhibitors (PPIs) are frequently used to treat gastroesophageal reflux disease (GERD) in children, but recent evidence suggests a potential association between PPI treatment and some types of infections. The aim of this study was to assess the effectiveness of Lactobacillus rhamnosus GG (LGG) for the prevention of gastrointestinal and respiratory tract infections in children with GERD treated with PPI (omeprazol). METHODS: Children younger than 5 years with GERD were assigned by a computer-generated list to receive LGG (10(9) colony-forming units) or placebo, twice daily, concomitantly with PPI treatment for 4–6 weeks; they were followed up for 12 weeks after therapy. The primary outcome measures were the percentage of children with a minimum of one episode of respiratory tract infection and the percentage of children with a minimum of one episode of gastrointestinal infection during the study. RESULTS: Of 61 randomized children, 59 patients (LGG n=30; placebo n=29, mean age 11.3 months) were analyzed. There was no significant difference found between the LGG and placebo groups, either for the proportion of children with at least one respiratory tract infection (22/30 vs. 25/29, respectively; relative risk [RR] 0.85, 95% confidence interval [CI] 0.66–1.10) or for the proportion of children with at least one gastrointestinal infection (9/30 vs. 9/29, respectively; RR 0.97, 95% CI 0.45–2.09). CONCLUSION: LGG was not effective in the prevention of infectious complications in children with GERD receiving PPI. Caution is needed in interpreting these results, as the study was terminated early due to slow subject recruitment.
format Online
Article
Text
id pubmed-7231745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition
record_format MEDLINE/PubMed
spelling pubmed-72317452020-05-31 Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial Dziechciarz, Piotr Krenke, Katarzyna Szajewska, Hania Horvath, Andrea Pediatr Gastroenterol Hepatol Nutr Original Article PURPOSE: Proton-pump inhibitors (PPIs) are frequently used to treat gastroesophageal reflux disease (GERD) in children, but recent evidence suggests a potential association between PPI treatment and some types of infections. The aim of this study was to assess the effectiveness of Lactobacillus rhamnosus GG (LGG) for the prevention of gastrointestinal and respiratory tract infections in children with GERD treated with PPI (omeprazol). METHODS: Children younger than 5 years with GERD were assigned by a computer-generated list to receive LGG (10(9) colony-forming units) or placebo, twice daily, concomitantly with PPI treatment for 4–6 weeks; they were followed up for 12 weeks after therapy. The primary outcome measures were the percentage of children with a minimum of one episode of respiratory tract infection and the percentage of children with a minimum of one episode of gastrointestinal infection during the study. RESULTS: Of 61 randomized children, 59 patients (LGG n=30; placebo n=29, mean age 11.3 months) were analyzed. There was no significant difference found between the LGG and placebo groups, either for the proportion of children with at least one respiratory tract infection (22/30 vs. 25/29, respectively; relative risk [RR] 0.85, 95% confidence interval [CI] 0.66–1.10) or for the proportion of children with at least one gastrointestinal infection (9/30 vs. 9/29, respectively; RR 0.97, 95% CI 0.45–2.09). CONCLUSION: LGG was not effective in the prevention of infectious complications in children with GERD receiving PPI. Caution is needed in interpreting these results, as the study was terminated early due to slow subject recruitment. The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020-05 2020-05-08 /pmc/articles/PMC7231745/ /pubmed/32483546 http://dx.doi.org/10.5223/pghn.2020.23.3.251 Text en Copyright © 2020 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition https://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Dziechciarz, Piotr
Krenke, Katarzyna
Szajewska, Hania
Horvath, Andrea
Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
title Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
title_full Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
title_fullStr Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
title_full_unstemmed Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
title_short Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
title_sort lactobacillus rhamnosus gg usage in the prevention of gastrointestinal and respiratory tract infections in children with gastroesophageal reflux disease treated with proton pump inhibitors: a randomized double-blinded placebo-controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231745/
https://www.ncbi.nlm.nih.gov/pubmed/32483546
http://dx.doi.org/10.5223/pghn.2020.23.3.251
work_keys_str_mv AT dziechciarzpiotr lactobacillusrhamnosusggusageinthepreventionofgastrointestinalandrespiratorytractinfectionsinchildrenwithgastroesophagealrefluxdiseasetreatedwithprotonpumpinhibitorsarandomizeddoubleblindedplacebocontrolledtrial
AT krenkekatarzyna lactobacillusrhamnosusggusageinthepreventionofgastrointestinalandrespiratorytractinfectionsinchildrenwithgastroesophagealrefluxdiseasetreatedwithprotonpumpinhibitorsarandomizeddoubleblindedplacebocontrolledtrial
AT szajewskahania lactobacillusrhamnosusggusageinthepreventionofgastrointestinalandrespiratorytractinfectionsinchildrenwithgastroesophagealrefluxdiseasetreatedwithprotonpumpinhibitorsarandomizeddoubleblindedplacebocontrolledtrial
AT horvathandrea lactobacillusrhamnosusggusageinthepreventionofgastrointestinalandrespiratorytractinfectionsinchildrenwithgastroesophagealrefluxdiseasetreatedwithprotonpumpinhibitorsarandomizeddoubleblindedplacebocontrolledtrial